key: cord-0988514-qi0qw7np
authors: Yang, Limin; Tian, Deyu; Han, Jian-bao; Fan, Wenhui; Zhang, Yuan; Li, Yunlong; Sun, Wenqiang; Wei, Yanqiu; Tian, Xiaodong; Yu, Dan-dan; Feng, Xiao-li; Cheng, Gong; Bi, Yuhai; Zheng, Yong-tang; Liu, Wenjun
title: A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates
date: 2021-06-19
journal: Innovation (N Y)
DOI: 10.1016/j.xinn.2021.100140
sha: adb17bed49643f2beb38be94e285349cf0ea2ae9
doc_id: 988514
cord_uid: qi0qw7np

A safe and effective vaccine is critical to combat the COVID-19 pandemic. Here, we developed a trimeric SARS-CoV-2 receptor-binding domain (RBD) subunit vaccine candidate that simulates the natural structure of the spike (S) trimer glycoprotein. Immunization with the RBD-trimer induced robust humoral and cellular immune responses, and a high level of neutralizing antibodies was maintained for at least 4.5 months. Moreover, the antibodies that were produced in response to the vaccine effectively cross-neutralized the SARS-CoV-2 501Y.V2 variant (B.1.351). Of note, when the vaccine-induced antibodies dropped to a sufficiently low level, only one boost quickly activated the anamnestic immune response, conferring full protection against a SARS-CoV-2 challenge in rhesus macaques without typical histopathological changes in the lung tissues. These results demonstrated that the SARS-CoV-2 RBD-trimer vaccine candidate is highly immunogenic and safe, providing long-lasting, broad, and significant immunity protection in nonhuman primates, thereby offering an optimal vaccination strategy against COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent for the novel coronavirus disease (COVID- 19) , 1 mediates receptor binding and cell entry and is the primary target for vaccine design. 16 To mimic the native S trimer structure, an artificially designed S trimer was constructed by fusing the C-terminal region of human type Iα collagen, and this construct was used for vaccine research. 17 Previous studies have found that both SARS-CoV and MERS-CoV display antibody-dependent enhancement (ADE), which may increase the risk of vaccinations enhancing viral infection. 18, 19 The primary mechanism is that the non-neutralizing antibodies produced in response to the vaccine mediate virus infection via the fragment crystallizable (Fc) receptor. 19 A recent study J o u r n a l P r e -p r o o f has proved that antibodies against the S protein N-terminal-domain (NTD) enhanced the binding capacity of S protein to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and infectivity of SARS-CoV-2. 20 Hence, the potential ADE effect needs to be carefully considered in designing COVID-19 vaccines. To mitigate the ADE effect, minimizing non-neutralizing epitopes and keeping only the critical neutralizing epitope to elicit robust protective immunity is a solution. The receptor-binding domain (RBD) located at the C-terminus of the S1 subunit has thus attracted attention. Several lines of evidence have indicated that RBD-specific antibodies could minimize the ADE effect, 21 and most discovered potent neutralizing antibodies (NAbs) target the RBD region. 22,23 SARS-CoV-2 initiates viral replication by binding via the RBD to ACE2. Hence, the RBD can be used as a vaccine target to block viral attachment. Additionally, the RBD possesses T cell epitopes, which can induce antiviral T cell responses. 12,13 However, the RBD has a low molecular weight, which leads to its weak immunogenicity. 14 Some researchers have tried to express the RBD by fusing it with the Fc domain or tandem repeat and preparing it as a dimer, thereby greatly enhancing its immunogenicity. 14,24 Some evidence has shown that the NAb level in SARS-CoV-2-infected humans significantly declines from the second month and can even be lost, 25 causing those individuals to be reinfected. 26 This short-lasting antibody protection poses a severe challenge for vaccine development. In addition, SARS-CoV-2 is characterized by a high mutation rate, and a growing body of evidence has shown that the 501Y.V2 variant (B.1.351), which emerged in South Africa, severely reduced the protective efficacy of mRNA vaccines. [27] [28] [29] Therefore, a J o u r n a l P r e -p r o o f vaccine strategy that can produce persistent and broad protection is particularly preferred.

In the present study, we designed and developed an RBD trimer as a candidate SARS-CoV-2 subunit vaccine. A single immunization elicited the rapid production of protective NAbs in all rhesus macaques. Booster immunization induced a robust immune response, and high NAb titers, CD4 + as well as CD8 + T cell immune responses developed. The immune protection period lasted for at least four months (neutralization titer > 100). Moreover, booster immunization could immediately activate the memory immune response, allowing an immunized individual to regain immune protection within a week. In addition, the vaccine-induced antibodies presented cross-neutralizing activity against the 501Y.V2 variant with slightly decreased potency. Our vaccine candidate conferred significant protection against SARS-CoV-2 infection in vaccinated nonhuman primates (NHPs).

To simulate the native SARS-CoV-2 S protein trimeric form and improve conformational homogeneity, a natural trimerization domain of T4 bacteriophage fibritin (foldon) was fused to the C-terminus of the SARS-CoV-2 RBD protein ( Figure 1A ). An interleukin-10 signal peptide was added to the N-terminus of the RBD to improve peptide secretion. The recombinant protein, named RBD-trimer, was ectopically expressed in human embryonic kidney (HEK293) cells. The RBD-trimer was purified by Ni-NTA affinity chromatography and gel filtration. The purity and antigenicity of the recombinant protein were assessed by SDS-PAGE ( Figure 1B ) and

Western blot ( Figure 1C ) assays under reducing and nonreducing conditions. With the help of foldon, the recombinant RBD protein polymerized into a stable homogeneous trimer (~100 kDa), which dissociated into monomers (~33 kDa) under reducing conditions. According to the N-terminal sequence of the RBD-trimer, the interleukin-10 signal peptide was efficiently cleaved off. The binding affinity of RBD trimer or monomer for recombinant ACE2 protein was determined using enzyme-linked immunosorbent assay (ELISA). The RBD-trimer demonstrated higher binding affinity than the monomer ( Figure 1D ). We chose the AddaVax adjuvant, an MF59-like nanoemulsion, to prepare our vaccine formula to better stimulate the cellular immune response. The AddaVax-adjuvanted RBD-trimer protein was used throughout the following immunization experiments in animals.

To investigate the immunogenicity of the SARS-CoV-2 RBD-trimer vaccine, showed that the neutralizing titers (half-maximal inhibitory concentration, NT 50 ) against the 501Y.V2 variant was approximately 1030, which was approximately 30% lower than that against the WT strain (NT 50 of 1500) ( Figure 2E and Figure S1B ), suggesting that our vaccine can elicit strong cross NAbs against 501Y.V2 variant.

Neither RBD-specific binding antibodies nor NAbs were detected in the sham-vaccinated macaques.

For evaluation of SARS-CoV-2-specific T cell responses, peripheral blood mononuclear cells (PBMCs) were isolated after the second dose, and the CD4 + and CD8 + T cells producing interferon-γ (IFN-γ) were measured by enzyme-linked immunospot (ELISPOT) and intracellular cytokine staining (ICS) assays. The level of IFN-γ secreted by PBMCs significantly increased in the SARS-CoV-2-S1 stimulation group compared with the sham group (140-440 spots/10 6 cells from 7-21 spots/10 6 cells, Figure 2F ). Moreover, the proportion of IFN-γ-secreting CD4 + T cells (IFN-γ + /CD4 + ) among all CD4 + T cells increased from 0.12% to 0.32-0.44% ( Figure   2G , I), and the proportion of IFN-γ-secreting CD8 + T cells (IFN-γ + /CD8 + ) reached 0.70-0.9% from 0.18% ( Figure 2H , J), demonstrating that immunization with J o u r n a l P r e -p r o o f

We next assessed the protective efficacy of the RBD-trimer vaccine against SARS-CoV-2 infection in rhesus macaques; all macaques were intranasally and tracheally challenged with 1×10 7 TCID 50 of the SARS-CoV-2 20SF107 strain 9 days after the second booster vaccination ( Figure 2A) . Throat, nose, rectal swabs, and tracheal brush specimens were collected at different times during post-infection. All animals were euthanized 7 days post-infection (dpi) to assess the viral load and lesions in the respiratory tissues. High concentrations of viral RNA were detected in swab specimens from the throat, nose, rectum, and tracheal brushes of the control animals throughout the experimental period (Figure 3 A, B, C, D) . The viral loads in nasal swabs and tracheal brushes of control macaques gradually decreased after peak values at 2 dpi. However, the viral loads in anal swabs increased gradually from 2 dpi, suggesting that the virus was excreted through the digestive tract. In contrast, a small amount of viral RNA was detected in the swabs and tracheal brushes at 1 dpi and then quickly dropped to an extremely low level in the RBD-trimer-immunized macaques.

All seven different lung lobe tissues from the control macaques showed high levels of viral genomic RNA. In contrast, no viral RNA was detected in the immunized macaques, indicating that our RBD vaccine candidate could confer full protective immunity in lung tissues ( Figure 3E ). Additionally, no clinical signs were found in the immunized macaques after challenge, while the control macaques exhibited J o u r n a l P r e -p r o o f symptoms of infection, including cough, malaise, and fervescence ( Figure 3F ).

Histopathological analysis of the fixed lung tissues was performed with hematoxylin-eosin (H&E) staining. No visible pathological change or inflammatory cell infiltration was observed in the lung tissues from immunized macaques ( Figure   4A , B). In contrast, severe histopathological changes were found in the control macaques, including apparent thickened alveolar walls, mononuclear inflammatory cell infiltration, focal exudation, hemorrhage, and architecture disappearance ( Figure   4C , D). Immunofluorescence staining assays showed that multiple pneumocytes in the lung sections from the control macaques were positive for SARS-CoV-2 S protein staining, especially along the airway ( Figure 4G , H). In contrast, no viral antigen was detected in the lung tissues from the immunized animals ( Figure 4E , F).

To further evaluate memory humoral and T cell immune responses in vaccinated macaques after challenge, paired serum and PBMCs were collected from vaccinated animals before and after SARS-CoV-2 challenge, and changes in the NAb titer and the percentage of CD4 + and CD8 + T cells producing cytokines in response to SARS-CoV-2 were analyzed. The results showed that the NAb titers did not change one week after viral challenge, indicating that no anamnestic humoral immune response was induced. Previous studies showed that when the vaccine candidate fails to generate a sufficient protective immune response, the challenge will enhance NAb titers 12 ; therefore, our vaccine protection is highly effective. Simultaneously, the proportions of CD4 + and CD8 + T cells secreting IFN-γ, interleukin-2 (IL-2), IL-4 and [27] [28] [29] This increases the risk of infection after vaccination. Adenovirus vector vaccines require high doses to achieve the expected immune protection due to pre-existing immunity, which increases the risk of side effects. Moreover, they were found to be associated with rare cases of blood clots after vaccination. 30 Inactivated vaccines can induce antibody production but cannot effectively elicit a cellular immune response.

Although antibodies have been shown to play a critical role in protection against coronavirus infections, the T cell response is still indispensable for virus clearance, decreasing severe illness, and prognostic recovery. 31 Subunit vaccines are considered the safest vaccine strategy. Hepatitis B and human papillomavirus subunit vaccines, which have been widely administered, showed good safety. A SARS-CoV-2 RBD-Fc fusion subunit vaccine can induce a strong humoral immune response in NHPs but fails to develop a T cell response. After challenge, high concentrations of viral RNA were detected in the lungs of vaccinated NHPs, suggesting that the vaccine did not provide adequate protection. 24 Another RBD tandem repeat dimer vaccine was also unable to elicit a T cell response in mice model. 14 To improve the immunogenicity of the recombinant RBD protein and better mimic the native trimeric SARS-CoV-2 S structure, we fused a trimer motif to make the RBD form a stable trimer structure; the construct will not dissociate even if the temperature is above 60℃, and there was no change after 3 months of storage at 4℃.

Western blot analysis showed that compared with the monomer, the trimer binds to the SARS-CoV-2 S1 polyclonal antibody more strongly, suggesting that the conformational epitope is better retained. NHPs can obtain protective NAb levels (EC 50 titer of 100) with a single dose of our candidate vaccine, indicating that it can be used for emergency vaccination of high-risk populations. There are few reports about the persistence of NAb responses induced by COVID-19 vaccine candidates. To evaluate the candidate's protection persistence, our immunity cycle spanned half a

year. The results showed that 18 weeks after the second vaccination, the antibody level gradually decreased to an EC 50 NAbs titers of 130. Although the antibody level was much lower than that immediately after vaccination, it was still higher than the protective antibody level (≥ 50 EC 50 ), 6 suggesting that this vaccine can achieve no less than 4.5 months of long-lasting humoral protection. Moreover, the vaccine-induced cellular immune response also helps extend the immune protection period due to the virus-specific memory T cells that can be maintained for a long to be more easily transmitted. 33,34 There is a growing concern that variants harboring RBD mutations could impair the protective efficacy of vaccines. 28, 29, 35 Therefore, the broadly protective effects of the vaccine are also a focus of our attention. Previous research reported that squalene-based adjuvants, such as MF59 or AF03, could increase the broadly protective potency of the influenza virus vaccine by stimulating a cross-neutralizing humoral response. 36, 37 Compared with aluminum adjuvants, squalene-based adjuvants have been shown to induce a more balanced humoral and cellular immune responses. 38 Therefore, we chose the AddaVax adjuvant, a squalene-based oil-in-water emulsion similar to MF59, to formulate our candidate vaccine. Excitingly, the antibodies produced in response to our vaccine showed good cross-neutralizing activity against the N501Y.V2 variant with slightly decreased potency. In addition, high titers of NAbs better prevent the immune escape of evolving variants, 28 This result is contrary to a previous report of an inactivated vaccine. 6 We think that this adjuvant or our formula is not suitable for the mouse model, which leads to immune weakness. Considering the international 3R principle (replacement, reduction and refinement), we aimed to minimize the number of NHPs, so we only used five experimental monkeys in this project. Due to the limitation of the number of experimental animals, most of our data cannot reach significant differences.

NAbs are considered to play a vital role in preventing SARS-CoV-2 infections.

However, the T cell immune response is also a critical effector in virus clearance and clinical symptom alleviation. 31 Moreover, previous studies have shown that the duration of the memory T cell response induced by infection is much longer than that of antibody level alterations, so cellular immunity is crucial for the durability of vaccine protection. 32, 39, 40 Additionally, as the level of NAbs gradually decreases after vaccination or infection, non-neutralizing antibodies may promote infection via the ADE effect. Nevertheless, virus-specific T cell immunity can reduce this potential

risk. An ideal vaccine should be able to induce humoral and cellular immune responses in a balanced manner. Compared with the RBD monomer, the RBD-trimer generated a higher level of NAbs, resulting in more potent protection. It is surprising that by formulating an AddaVax adjuvant, our vaccine candidate also demonstrated a strong CD4 + and CD8 + T cell immune response in NHPs; the T helper 1 (T H 1) cells and cytotoxic T cells promote the elimination of virus-infected cells, conferring robust protection. SARS-CoV-2 infects hosts mainly in the respiratory tract and lung, and pneumonia is the typical symptom of COVID-19. 41, 42 In this study, sham-immunized macaques showed severe pneumonia, whereas macaques immunized with our vaccine candidate exhibited significant protection. Furthermore, no viral RNA or S protein was detected in the lungs of the immunized macaques by qPCR or immunostaining assays, which proved that the vaccine candidate conferred full immunity protection.

SARS-CoV-2 attacks host organs beyond the lung; liver injury has also been recorded. 43 In this work, after challenge, the ALT and AST values of the unimmunized animals increased, indicating liver lesions caused by SARS-CoV-2.

There were no abnormalities in the vaccinated animals, which means that our vaccine candidate may protect the animals from liver injury. In short, our candidate vaccine can effectively protect the organs of NHPs from virus attacks.

Compared with young people, the frail middle-aged population has higher risks of severe COVID-19 and a higher mortality rate, and the virus replicates more efficiently in their lungs and other organs. 44, 45 Therefore, the development of vaccines that offer protection to middle-aged and frail people is particularly valuable. Thus, our vaccination group included a frail macaque (#140829, 6 years old, 4.8 kg), which was only half the weight of macaques of the same age. This animal can better simulate the candidate vaccine's immune and protective efficacy in frail people. Compared to the other two macaques, the frail macaque had a slightly weaker immune response and lower antibody levels during the first two vaccinations. However, after the third immunization, its immune responses were no different from those of the other macaques. This frail monkey was also fully protected by RBD-trimer vaccination, suggesting that it could provide adequate protection against COVID-19 to middle-aged and frail people. In summary, our RBD-based subunit vaccine candidate induced robust humoral and cellular immune responses and protected NHPs against SARS-CoV-2 infection, and it also showed good safety. There were no abnormalities in body temperature, weight, clinical signs, pathology, hematology, or biochemical indicators during vaccination and viral challenge. These data proved the possibility that our RBD-trimer is a promising candidate vaccine to prevent COVID-19. 

Epidemiological and clinical characteristics of 99 10

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice

Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

Seasonal coronavirus protective immunity is short-lasting

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies

Comparison of adjuvants to optimize influenza neutralizing antibody responses

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical Characteristics of Coronavirus Disease 2019 in China

Liver injury in COVID-19: management and challenges

Predictive Model and Risk Factors for Case Fatality of COVID-19: A Cohort of 21,392 Cases in Hubei, China. The Innovation 1, 100022

Predicting Illness Severity and Short-Term Outcomes of COVID-19: A Retrospective Cohort Study in China. The Innovation 1, 100007

We thank Junfeng Shi and Jinhui Zhang from Beijing Primabio Inc. for their assistance with husbandry and experiments. We thank Yutong Wu from UC Berkeley for her assistance with language polishing. This study was funded by National Key Technologies Research and Development Program grants 2018YFC1200600 and